Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study

Auteurs

S. Delaloge, D. Pérol, C. Courtinard, E. Brain, B. Asselain, T. Bachelot, M. Debled, V. Dieras, M. Campone, C. Levy, W. Jacot, V. Lorgis, C. Veyret, F. Dalenc, J.M. Ferrero, L. Uwer, P. Kerbrat, A. Goncalves, M.A. Mouret-Reynier, T. Petit, C. Jouannaud, L. Vanlemmens, G. Chenuc, T. Guesmia, M. Robain, C. Cailliot